Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

11.06 -0.10 (-0.85%)
Streaming Delayed Price Updated: 1:14 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
News headline image
China-Based COVID-19 Shot Neutralizes Omicron Subvariants ↗
 
Via Benzinga
News headline image
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
News headline image
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations ↗
Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).  
Via Benzinga
News headline image
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
News headline image
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Dynavax Technologies: Q2 Earnings Insights ↗
Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences Stock Shows Rising Relative Strength ↗
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
News headline image
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
News headline image
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier. 
Via Investor's Business Daily
News headline image
7 Small-Cap Stocks to Buy in July 2022 ↗
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
News headline image
56 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to... 
Via Benzinga
News headline image
110 Biggest Movers From Friday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action ↗
 
Via Benzinga
News headline image
Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: Dynavax Technologies Q4 Earnings ↗
Dynavax Technologies (NASDAQ:DVAX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.